REPORT CARD RESULTS
Public Citizen
American Autoimmune Related Diseases Association (AARDA)
Drug Companies: Abbott Laboratories, Forest Laboratories and King Pharmaceuticals
Dairy Queen
Endocrinology Researchers
America's Doctors
Holistic/Alternative Medicine Community
American Academy of Clinical Endocrinologists (AACE)
U.S. Food and Drug Administration (FDA)
Larry Ladd, Perchlorate Activist
Drug Companies, Attorneys for the Synthroid Class Action Lawsuit
PDF Printer-friendly version of 2004 Thyroid Disease Report Card
aaaaaaaaa
|
|
 |
Drug Companies: Abbott Laboratories, Forest Laboratories and King Pharmaceuticals
Grade: D
The thyroid drug companies have not exactly shown themselves to be particularly customer-focused in 2003. Abbott Laboratories has attempted to hang on to market share, by arguing that the methodology used to approve a “generic” version of levothyroxine – and in particular, their top-selling thyroid drug Synthroid -- is flawed, and that until the method is changed, no generic to Synthroid should be approved. Meanwhile, Synthroid is still inexplicably substantially more expensive than its competitors’ levothyroxine products in many markets. Since Synthroid has a virtual lock on the market with many endocrinologists, this leaves patients – and insurers – paying more for a product that hasn’t been shown to be any better than its competitors.
Forest Laboratories saw the FDA ban further production of their levothyroxine drug, Levothroid, because it had still failed to obtain FDA approval, a move ordered back in 1997 by the FDA. The company finally ended up getting back into the market by re-releasing Levothroid using Llloyd Pharmaceutical's FDA-approved levothyroxine formulation. FDA concerns about the manufacturing of Thyrolar, Forest’s synthetic T4/T3 drug, have resulted in stalled production, and a lack of availability throughout the nation, leaving patients high and dry, and the company refusing to provide an estimated date when the product will return to the market.
As for King Pharmaceuticals, all we have to say are two words: “Levoxyl recalls!” The company’s levothyroxine drug, the second most popular levothyroxine after Synthroid, has faced recall after recall in 2003, for various quality and potency problems, causing some patients to give up entirely and switch to other drugs.
Search My Thyroid Sites
I run two large thyroid sites, so search both sites to see if your topic is covered.
|
|
Sticking Out Our
Necks and this website are © Copyright Mary
Shomon, 1997-2003. All rights reserved. Mary
Shomon, Editor/Webmaster
All
information is intended for your general knowledge only and is not a
substitute for medical advice or treatment for specific medical
conditions. You should seek prompt medical care for any specific health
issues and consult your physician or health practitioner before starting a
new treatment program. Please see our full disclaimer.
|
|